WNK1-IN-1

Cat. No.:	HY-151545			
CAS No.:	324022-39-1			
Molecular Formula:	C ₁₃ H ₁₅ BrCl ₂ N ₂ O ₄ S			
Molecular Weight:	446.14			
Target:	Ser/Thr Protease			
Pathway:	Metabolic Enzyme/Protease			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	6 months	
		-20°C	1 month	

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (224.14 mM; Need ultrasonic)							
Preparing Stock Solutions	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg			
		1 mM	2.2414 mL	11.2072 mL	22.4145 mL			
	5 mM	0.4483 mL	2.2414 mL	4.4829 mL				
	10 mM	0.2241 mL	1.1207 mL	2.2414 mL				
	Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent o Solubility: 2.5 mg/	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (5.60 mM); Clear solution; Need ultrasonic						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (5.60 mM); Clear solution; Need ultrasonic							
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (5.60 mM); Clear solution; Need ultrasonic							

Description	WNK1-IN-1 is a selective inhibitor of WNK1 with an IC ₅₀ value of 1.6 μM. WNK1-IN-1 inhibits OSR1 phosphorylation with an IC ₅₀ value of 4.3 μM. WNK1-IN-1 can be used for the research of blood pressure regulation and cancer ^[1] .				
IC_{50} & Target	IC50: 1.6 μ M (WNK1), 4.3 μ M (OSR1 phosphorylation) ^[1]				
In Vitro	WNK1-IN-1 (0-1000 μM; 30 min) shows high potency to WNK1 with an IC ₅₀ value of 1.6 μM ^[1] . WNK1-IN-1 (0.2-12.5 μM; 24 h) inhibits endogenous OSR1 phosphorylation with an IC ₅₀ value of 4.3 μM in MDAMB231 breast-				

0

ίς, Έλληνος

O

ĊI

CI

Br

0 || N^+

NH

0-



cancer cells^[1].

WNK1-IN-1 (0-100 mM) is 10-fold more potent to WNK1 than WNK3 in Kinase-Glo assay^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Rodriguez M, et al. Synthesis and Structural Characterization of Novel Trihalo-sulfone Inhibitors of WNK1. ACS Med Chem Lett. 2022 Sep 23;13(10):1678-1684.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA